Study of iruplinalkib after lorlatinib for ALK-positive lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial is for people with advanced lung cancer whose tumors have an ALK gene change and who have already taken a medicine called lorlatinib. It tests a new drug, iruplinalkib, to see how well it works for those who stopped responding to or couldn't tolerate lorlatinib.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have advanced lung adenocarcinoma (a type of lung cancer).
- Your cancer must have an ALK gene change confirmed by a special lab test.
- You must have taken lorlatinib before and had your cancer get worse while on it, or you had side effects that stopped you from taking it.
- You must have started taking iruplinalkib in a real-world setting (not as part of another study).
- You cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a targeted therapy called lorlatinib in people with advanced ALK-positive lung cancer. It aims to see how well this oral medication works in a real-world setting.
This study tests a combination of two targeted medicines for people with a specific type of non-small cell lung cancer (NSCLC) that has the ALK gene change. The goal is to see if giving these drugs before surgery can shrink tumors and improve outcomes.
This trial tests a targeted pill, lorlatinib, for people with advanced ALK-positive non-small cell lung cancer (NSCLC) who have not received previous treatment for advanced disease. It aims to see how well the drug works in this setting.
This study looks at different ways to manage high cholesterol (hyperlipidemia) that happens as a side effect of the drug lorlatinib, which is used to treat ALK-positive lung cancer. Participants will receive additional cholesterol-lowering medicines or strategies, and the study aims to find the best way to keep cholesterol in check while continuing effective cancer treatment.
This study follows people with alk-positive non-small cell lung cancer who are taking iruplinalkib to see how well it works and how safe it is in real life. It helps doctors learn more about the drug's effects outside of clinical trials.
This study tests whether taking a pill called iruplinalkib after surgery for early-stage ALK-positive lung cancer can help keep cancer from coming back. Iruplinalkib is a type of targeted therapy that blocks cancer cells with a specific ALK gene change.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.